News headlines about Titan Pharmaceuticals (NASDAQ:TTNP) have been trending somewhat positive on Thursday, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Titan Pharmaceuticals earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 44.933034596232 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Titan Pharmaceuticals (TTNP) traded down $0.05 on Thursday, reaching $1.35. 70,500 shares of the company were exchanged, compared to its average volume of 60,750. The stock has a market capitalization of $29.16, a P/E ratio of -2.21 and a beta of 2.07. The company has a debt-to-equity ratio of 1.67, a current ratio of 6.12 and a quick ratio of 6.12. Titan Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $4.80.
Titan Pharmaceuticals (NASDAQ:TTNP) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.17 million. Titan Pharmaceuticals had a negative net margin of 6,757.29% and a negative return on equity of 146.81%. research analysts anticipate that Titan Pharmaceuticals will post -0.67 EPS for the current year.
Separately, Roth Capital reaffirmed a “buy” rating and issued a $6.00 target price on shares of Titan Pharmaceuticals in a research note on Thursday, October 5th.
ILLEGAL ACTIVITY WARNING: This article was reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2018/01/04/titan-pharmaceuticals-ttnp-receiving-somewhat-positive-news-coverage-accern-reports.html.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.